Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.65 |
| ▸ | ADA | P00813 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-B-Methyl-Guanosine SCHEMBL18537403 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL12149502 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10208618 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL15187539 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10819905 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL18537392 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL14842089 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL12758165 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL14946249 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-9243025-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | ADORA2A 92/4885ADA 14/4885ADORA3 114/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ADORA2A 85/4885ADA 8/4885ADORA3 103/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ADORA2A 85/4885ADA 8/4885ADORA3 103/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | ADORA2A 1132/4885ADA 263/4885ADORA3 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.